-
1.发明申请公开(公告)号：US20170088896A1
公开(公告)日：2017-03-30
申请号：US15311737
申请日：2015-05-15
Inventor： Gurjit Khurana Hershey , Jocelyn Biagini Myers , Hong Ji , Lisa J. Martin
IPC: C12Q1/68 , A61K31/215 , A61K31/145 , A61K9/00 , G01N33/68 , A61K31/573
CPC classification number: C12Q1/6883 , A61K9/0073 , A61K31/145 , A61K31/215 , A61K31/573 , C12Q2600/106 , C12Q2600/158 , C12Q2600/16 , G01N33/6893 , G01N2333/98 , G01N2800/122
Abstract: Provided herein are methods and kits related to use of vanin-1 (VNN1) expression for assessing responsiveness to steroid treatment in subjects with asthma and for treating subjects with asthma.
-
公开(公告)号：US12171740B2
公开(公告)日：2024-12-24
申请号：US18080057
申请日：2022-12-13
Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
Inventor： Nurit P. Azouz , Marc E. Rothenberg
IPC: A61K31/352 , A61K31/37 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K38/00 , A61K38/55 , A61K38/57 , A61K39/395 , A61P37/08 , C12N15/113
Abstract: Provided are methods for increasing SPINK7 anti-proteinase activity in a target tissue of a subject having an allergic inflammatory condition characterized by inflammation of a squamous epithelium in the target tissue, the method comprising inhibiting kallikrein 5 (KLK5) proteinase activity in the target tissue. Suitable KLK5 inhibitors may include a KLK5-Fc fusion protein, a KLK5 anti-sense polynucleotide, a KLK5-directed miRNA, a KLK5-directed shRNA, a KLK5-directed antibody, or a coumarin compound such as 3-(3-chlorophenyl) carboxy-7-hydroxymethyl coumarin or 3-carboxy-7-hydroxymethyl coumarin.
-
公开(公告)号：US20240418714A1
公开(公告)日：2024-12-19
申请号：US18602128
申请日：2024-03-12
Applicant: Children's Hospital Medical Center
Inventor： Hermine I. Brunner , Michael R. Bennett , Prasad Devarajan
IPC: G01N33/564 , A61K31/664 , G16H10/40
Abstract: Disclosed herein are methods for forecasting response to lupus nephritis (LN) therapy in individual diagnosed with childhood-onset SLE (cSLE). The methods may include the step of detecting each protein in a protein set in a sample obtained from an individual in need thereof. The protein set may include ceruloplasmin, kidney injury molecule 1 (KIM-1), monocyte chemotactic protein 1 (MCP-1), adiponectin, hemopexin, and NGAL.
-
公开(公告)号：US20240400628A1
公开(公告)日：2024-12-05
申请号：US18786697
申请日：2024-07-29
Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER , THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
Inventor： Douglas MILLAY , Dilani GAMAGE , Leonid CHERNOMORDIK , Evgenia LEIKINA
Abstract: Some embodiments of the invention include polypeptides comprising a myomerger polypeptide or an extracellular myomerger polypeptide. Other embodiments of the invention include nucleic acid molecules encoding polypeptides comprising a myomerger polypeptide or an extracellular myomerger polypeptide. Other embodiments of the invention include vectors comprising the nucleic acid molecule. Yet other embodiments of the invention include methods of using a myomerger poly peptide or an extracellular myomerger polypeptide. Additional embodiments of the invention are also discussed herein.
-
公开(公告)号：US20240316176A1
公开(公告)日：2024-09-26
申请号：US18490287
申请日：2023-10-19
Applicant: Children's Hospital Medical Center
IPC: A61K39/12 , A61K39/00 , A61K39/385 , A61P31/14 , C07K14/005 , C12N7/00
CPC classification number: A61K39/12 , A61K39/385 , A61P31/14 , C07K14/005 , C12N7/00 , A61K2039/6075 , A61K2039/64 , A61K2039/70 , C07K2319/33 , C12N2770/16022 , C12N2770/16034
Abstract: Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.
-
Patent Agency Ranking
公开(公告)号：US12054526B2
公开(公告)日：2024-08-06
申请号：US17251019
申请日：2019-06-14
Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER , THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
Inventor： Douglas Millay , Dilani Gamage , Leonid Chernomordik , Evgenia Leikina
CPC classification number: C07K14/4716 , A61K38/17 , C12N5/16 , A61K38/00
Abstract: Some embodiments of the invention include polypeptides comprising a myomerger polypeptide or an extracellular myomerger polypeptide. Other embodiments of the invention include nucleic acid molecules encoding polypeptides comprising a myomerger polypeptide or an extracellular myomerger polypeptide. Other embodiments of the invention include vectors comprising the nucleic acid molecule. Yet other embodiments of the invention include methods of using a myomerger polypeptide or an extracellular myomerger polypeptide. Additional embodiments of the invention are also discussed herein.
-
公开(公告)号：US20240124566A1
公开(公告)日：2024-04-18
申请号：US18499353
申请日：2023-11-01
Applicant: Children's Hospital Medical Center
Inventor： Sonata Jodele , Tsuyoshi Fukuda , Kana Mizuno
CPC classification number: C07K16/18 , A61P9/10 , A61P37/02 , G01N33/6893 , G16H20/17 , A61K2039/545
Abstract: Described are methods and systems for the treatment of individuals having a disorder characterized by complement system dysregulation. The described methods and systems may be used for a variety of purposes, including for example, establishing one or both of a general or personalized dosing schedule for treatment using a complement inhibitor, establishing a dosage schedule sufficient to maintain an effective amount of complement inhibitor, establishing general dosing schedules for novel complement modifying agents and identifying a treatment regimen and/or dose eliminating the possibility of under dosing medication, and treatment regimen and/or dose for reducing or preventing toxicity in a patient.
-
8.发明公开公开(公告)号：US20240003904A1
公开(公告)日：2024-01-04
申请号：US18325890
申请日：2023-05-30
Applicant: Children's Hospital Medical Center
Inventor： Hector R. Wong
IPC: G01N33/68
CPC classification number: G01N33/6869 , G01N2800/56
Abstract: Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to persistent multiple organ dysfunction syndrome (MODS) in pediatric patients following cardiopulmonary bypass (CPB). Certain aspects of the disclosure relates to identifying one or more biomarkers associated with septic shock in pediatric patients, obtaining one or more samples from a pediatric patient following CPB, then quantifying from the sample an amount of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.
-
公开(公告)号：US11844600B2
公开(公告)日：2023-12-19
申请号：US17321915
申请日：2021-05-17
Applicant: Children's Hospital Medical Center
Inventor： Charles L Dumoulin
CPC classification number: A61B5/055 , A61B5/416 , A61B6/04 , A61G7/103 , A61G13/1285 , A61B2503/045
Abstract: A patient table adapted for use in association with an MR scanner for neonatal infants is provided. The patient table has an extendable patient bed attached to and extendable from the patient table. The patient bed may be at least partially inserted into an MR scanner without requiring the patient table to enter the MR scanner. A transport mechanism is on the underside of the patient table so that it may be readily moved over the floor on which it rests. The patient table includes a latching mechanism that may operate to releasably attach the patient table to a patient table docking assembly. The docking assembly is operative to selectively move the patient table towards, into and away from the MR scanner.
-
公开(公告)号：US20230400473A1
公开(公告)日：2023-12-14
申请号：US18207707
申请日：2023-06-09
Applicant: Children's Hospital Medical Center
Inventor： Phillip Minar , Anil G. Jegga
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N2800/065 , G01N2800/52 , G01N2333/9123 , G01N2333/70578 , G01N2333/96433 , G01N2333/4713 , G01N2333/70535
Abstract: Disclosed herein anti-TNF therapy companion diagnostics (e.g., a predictive biomarker panel) for management of Crohn's Disease (CD). The disclosed companion diagnostics may be used to identify an appropriate treatment for a patient, and includes, for example, in vitro diagnostic tests or devices that provide information for the use of an anti-TNF therapy. The disclosed methods may be used, in certain aspects, for the identification of patients likely to respond, or as not likely to respond to an anti-TNF agent. The use of the disclosed methods may allow for dose determination, discontinuation, or the administration of combinations of therapeutic agents.
-
-
-
-
-
-
-
-
-
Search Results
608
records
(took 0.026 seconds)
